Researchers found that Ga-68 DOTATATE PET/MRI was able to detect 61% malignant progressive and recurrent lesions and 23% low-avid lesions, confirm osseous and parenchymal invasion and improve extent-of-disease visualization without prolonging acquisition times in individuals with clinically suspected or pathology-proven meningioma. The findings, presented at the Radiological Society of North America's annual meeting, led researchers to conclude that Ga-68 DOTATATE may help guide post-treatment meningioma evaluations.
Ga-68 DOTATATE PET/MRI may better assess meningioma treatment response
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.